linjc16/ctgov huggingface dataset:
The Effect of Cancer Pain Management Protocol on Hospitalized Cancer Patients: A Pilot Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to prospectively evaluate the effect of cancer pain management protocol on hospitalized cancer patients.

Official Title
-----------------
A Pilot Study: The Effect of Cancer Pain Management Protocol on Hospitalized Cancer Patients

Conditions
-----------------
Cancers, Pain

Intervention / Treatment
-----------------
* Drug: Cancer pain management


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized patient with the somatic and/or visceral pain having an untreated intensity greater than 3 on a 10 cm visual analog scale (VAS; 0 = no pain, 10 = unbearable pain)over the week prior to enrollment A minimum age of 18 years Exclusion Criteria: Opioid intolerance No longer treatment for their underlying disease. Intracerebral primary or metastatic lesion Impaired sensory or cognitive function Pregnant or lactating woman Women of child bearing potential not using a contraceptive method Sexually active fertile men not using effective birth control during medication of study drug and up to 6 months after completion of study drug if their partners are women of child-bearing potential Any patients judged by the investigator to be unfit to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pain control<br>Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician. | Drug: Cancer pain management<br>* Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in pain scores |  | Jan 2010 - October 2010 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer pain, opioid, guideline
Sonographic Characteristics of Tumor Indices in Patients With Cervical Cancer During Chemo-radiotherpy

Study Overview
=================
Brief Summary
-----------------
Cervical tumors are characterized by vascular changes (in terms of quantity, volume and Flows) in the tumor. Due to a good access to the cervix through the vagina, these parameters can be assessed using a three dimensional supersonic. Sonographic characteristics of tumor indices measures before and after oncological treatments may shed light on the patient's prognosis.

Detailed Description
-----------------
no editional information. see above

Official Title
-----------------
Sonographic Characteristics of Tumor Indices in Patients With Cervical Cancer During Chemo-radiotherpy

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Device: ultrasound examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cervical cancer patients intended to undergo chemotherapy or radiation, or both Exclusion Criteria: no exclusions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: ultrasound examination|ultrasound and doppler studies to evaluate size and vascularity of tumor during radiotherapy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sonographic characteristics of cervical tumors | Sonographic characteristics of cervical tumors indices measures before and after oncological treatments may shed light on the patient's prognosis. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cervical tumors,vascular changes,Sonographic characteristics
Experience of an Emergency Intensive Care Unit During COVID-19 Pandemic

Study Overview
=================
Brief Summary
-----------------
COVID-19, which emerged in China in December 2019, has become a pandemic with its spread to many countries of the world. Emergency departments also carried out an important part of the fight against pandemics in our country/Turkey. The emergency department including an intensive care unit is very few in this country/Turkey and the only hospital, which has an Emergency Intensive Care Unit (EICU) in Istanbul, is the study center. Therefore, this retrospective study aimed to provide useful information about how an effective EICU should be, especially how to use them during pandemic periods.

Detailed Description
-----------------
COVID-19, which emerged in China in December 2019, has become a pandemic with its spread to many countries of the world. Emergency departments also carried out an important part of the fight against pandemics in our country/Turkey. The emergency department including an intensive care unit is very few in this country/Turkey and the only hospital, which has an Emergency Intensive Care Unit (EICU) in Istanbul, is the study center. Throughout the pandemic, many patients, including COVID-19 patients, were successfully followed up and discharged from EICU. With this study, the investigators expect to show the role of EICU during the pandemic. In addition, it will be seen that whether the patients, who are waiting for hospitalization or waiting for referral, are admitted to EICU faster and their treatments will be started promptly. Therefore, this retrospective study aimed to provide useful information about how an effective EICU should be, especially how to use them during pandemic periods.

Official Title
-----------------
Experience of an Emergency Intensive Care Unit During COVID-19 Pandemic: Retrospective Cohort Study

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Diagnostic Test: COVID-19 diagnostic PCR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who followed up in emergency department ICU with the diagnosis of COVID-19 Accepted to participate with an informed consent Exclusion Criteria: Patients under the age of 18 or more than 50 years declined to participate deaths caused by other than COVID-19

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: COVID-19 diagnostic PCR|Nasopharyngeal swab samples will be analyzed by PCR for COVID-19 DNA existence.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality of the COVID-19 patients | Mortality of the COVID-19 patients who followed up by emergency department ICU | 3 months |
A Virtual Intervention to Improve Medication Adherence in Pediatric Cancer: MedSupport

Study Overview
=================
Brief Summary
-----------------
To develop a cancer center level practice intervention to promote treatment adherence and reduce outcome disparities in pediatric cancer survivors

Detailed Description
-----------------
To conduct a pilot study to assess the feasibility and acceptability of the Social Determinants of Adherence intervention

Official Title
-----------------
A Virtual Intervention to Improve Medication Adherence in Pediatric Cancer: MedSupport

Conditions
-----------------
Medication Adherence

Intervention / Treatment
-----------------
* Behavioral: Patient participation
* Other: Clinician barrier reports


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parents/caregivers of pediatric patients must meet the following criteria to be eligible: Parents/guardians of child that has been diagnosed with any cancer. Parents/guardians of child with any cancer between age 0 and 18. Parents/guardians of child on home-based oral anti-cancer therapy or supportive care therapy. The clinician for the family agrees to participate in the study. Exclusion Criteria: Participants will be excluded from this study if unwilling or unable to complete the assessment in English

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention - Pediatric parent/caregiver<br>Questionnaires along with educational videos | Behavioral: Patient participation<br>* Questionnaire<br>|
| Experimental: Clinicians<br>Will complete pre and post survey about medication education practices | Other: Clinician barrier reports<br>* How many times a 7 question Survey on medication education practices is opened<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retention rates | Feasibility of intervention as assessed by retention rates | Up to 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility of universal SDOA screening | Will be assessed by results of SDOA questionnaire an 8 item questionnaire rated on a 5-point Likert scale (0-I never experienced this ; 5 - I experience this quite a lot) | up to 8 weeks | 
| Provider satisfaction with barrier reports | REDCap analytics will track the rate of opened barrier reports | up to 8 weeks |
Rheumatological Manifestations in Inflammatory Bowel Diseases

Study Overview
=================
Brief Summary
-----------------
IBD-related arthropathy is one of a group of inflammatory arthritides considered as seronegative spondyloarthropathies, a group of disorders that also includes ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and undifferentiated SpA. IBD-related SpA is mainly characterized by axial involvement but may also be associated with peripheral symptoms, such as synovitis, dactylitis, or enthesitis

Official Title
-----------------
Rheumatological Manifestations in Inflammatory Bowel Diseases

Conditions
-----------------
Inflammatory Bowel Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any patient with inflammatory bowel diseases complaining of rheumatological manifestations Exclusion Criteria: chronic hepatitis (c) patients Rheumatoid factor positive patients psoriatic patients. systemic lupus.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the prevalence of rheumatological manifestations in cases of corhn's and ulcerative colitis | evaluation of all cases for manifestations of rheumatological manifestations | one year |
Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study

Study Overview
=================
Brief Summary
-----------------
This project aims to evaluate the efficacy of autologous mesenchymal stem cell treatment to preserve insulin production and beta-cell mass in recently diagnosed patients with type 1 diabetes mellitus. The hypothesis to be tested is that an increased number of circulating mesenchymal stem cells will provide immune modulatory properties, and thereby stop the immune process in islets causing progressive beta-cell death.

Official Title
-----------------
Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study

Conditions
-----------------
Type 1 Diabetes Mellitus

Intervention / Treatment
-----------------
* Biological: autologous mesenchymal stem cell transplantation
* Procedure: sham transplantation of mesenchymal stem cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: fasting C-peptide >0.12 nmol/l within three weeks of diagnosis of type 1 diabetes Exclusion Criteria: body mass index (BMI) >30 unstable cardiovascular status incl. New York Heart Association (NYHA) class III/IV patients with known or previous malignancy active infections incl. serological evidence of infection with HIV, Treponema pallidum, hepatitis B (patients with serology consistent with previous vaccination and a history of vaccination are acceptable) or hepatitis C. immune suppressive treatment women being pregnant or nursing, or women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: sham transplantation of mesenchymal stem cells<br>control arm with sham transplantation | Procedure: sham transplantation of mesenchymal stem cells<br>* Placebo control for transplantation of mesenchymal stem cells<br>|
| Active Comparator: autologous mesenchymal stem cell transplantation<br>Active arm with transplantation of cells | Biological: autologous mesenchymal stem cell transplantation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ∆-change of C-peptide Area Under the Curve (AUC) (0-120 min) for a mixed meal tolerance test at two year follow-up when compared to pre-treatment values at enrolment. |  | ∆-change will be assessed as a difference between two years after transplantation/sham transplantation of mesenchymal stem cells when compared to before transplantation/sham transplantation, i.e. at time 0. |
Retrospective Review of Amino Acid Formula Use at a Children's Center

Study Overview
=================
Brief Summary
-----------------
This is a retrospective review of data documented in medical records.

Detailed Description
-----------------
This is a retrospective review of data documented in medical records of patients consuming an amino-acid based enteral formula at a pediatric care facility in the United States.

Official Title
-----------------
Retrospective Review of Amino Acid Formula Use at a Children's Center

Conditions
-----------------
Children Requiring Amino Acid-based Formula Tube Feeding, Enteral Feeding Intolerance

Intervention / Treatment
-----------------
* Other: Enteral Formula


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consuming or with a history of consuming an amino acid-based formula Exclusion Criteria: Medical records lacking information on consumption of an amino acid-based formula

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Enteral Tube fed children<br>Enteral Formula | Other: Enteral Formula<br>* Enteral Feeding with an amino acid-based formula<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Documented indication for formula use | Medical diagnosis | Up to 12 months before formula switch | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body weight | Body weight in kilograms | 12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch | 
| Length/height | Length or height (based on age) in centimeters | 12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch | 
| Formula volume consumption | Average of 7 days | 12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch | 
| Stool frequency | Average of 7 days | 12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch | 
| Stool consistency | Average of 7 days | 12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch | 
| Vomiting | Average of 7 days | 12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch |
An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)

Study Overview
=================
Brief Summary
-----------------
This observational study will evaluate Xeloda (capecitabine) monotherapy on the effect of disease-free survival in patients with colon cancer stage III (Duke C) after surgical resection. Data will be collected for 3 years.

Official Title
-----------------
The Efficacy of Adjuvant Chemotherapy With Capecitabine (Xeloda) Monotherapy in Patients With Colon Cancer Stage III (Duke C) Considering the Histopathology of the Tumour (AXEL)

Conditions
-----------------
Colorectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients, over the age of 18 years Presence of colon adenocarcinoma Surgical resection for colon cancer stage III (Duke C) Prior adjuvant therapy with Xeloda monotherapy Exclusion Criteria: Contraindications for Xeloda

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease-free survival |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety (Incidence of adverse events) |  | 3 years |
A Retrospective Register Study to Map the Frequency of Short Duration Atrial Fibrillation (AF) Among All Patients Admitted to Roskilde Sygehus in Denmark in 2010

Study Overview
=================
Brief Summary
-----------------
Retrospective observational study of patients with atrial fibrillation admitted to Roskilde University Hospital in 2010.

Detailed Description
-----------------
The study is a retrospective register study of all patients discharged from Roskilde Hospital with a primary diagnosis of AF in 2010. All data will be collected from the patient's medical records and only data from this specific admission will be recorded. No follow-up of the patients after discharge will be performed in this study. The study does not involve any randomization or any drug testing.

Official Title
-----------------
A Retrospective Register Study to Map the Frequency of Short Duration Atrial Fibrillation (AF) Among All Patients Admitted to Roskilde Sygehus in Denmark in 2010

Conditions
-----------------
Type of Atrial Fibrillation, Medical History, Current Treatment, Complications

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Atrial fibrillation Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Atrial fibrillation patients<br>All patients discharged from hospital with a diagnose of atrial fibrillation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atrial fibrillation, registry